Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Zepbound Tirzepatide Dosage Guide Cagrilintide Dosage and Weight Loss Guide PEP DOSE CagriSema misses noninferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% iPharmaCenter Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link